SUMMIT, N.J.--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ:CELG) today announced the appointment of
Gerald F. Masoudi as Executive Vice President, General Counsel and
Corporate Secretary, effective June 1, 2015. Mr. Masoudi will be
responsible for global legal strategy and will serve on the company's
Mr. Masoudi will succeed Lawrence V. Stein, Celgene's Executive Vice
President, General Counsel and Corporate Secretary since 2012, who is
retiring from Celgene following a distinguished business and legal
career that also included serving as General Counsel for Wyeth and
Genetics Institute and as a partner at the law firm Arnold & Porter.
"Larry Stein has served as a valued member of Celgene's senior
leadership team and provided the company important strategic legal
counsel," said Robert J. Hugin, Chairman and CEO of Celgene Corporation.
"Celgene is deeply grateful for Larry's significant contributions during
his tenure as General Counsel."
"Jerry brings a wealth of experience to Celgene" said Mr. Hugin. "His
deep understanding of regulatory policy and his significant
healthcare-related legal expertise will add valuable perspective to our
Mr. Masoudi joins Celgene from Covington & Burling LLP, a leading
international law firm, where he is a partner and serves as co-chair of
the Food and Drug practice group. At Covington, he has advised
multinational companies and trade associations on significant
litigation, enforcement, regulatory and public policy matters. Before
joining Covington, Mr. Masoudi served as Chief Counsel of the U.S. Food
and Drug Administration. Before joining FDA, Mr. Masoudi served as
Deputy Assistant Attorney General for international, policy and
appellate matters in the Antitrust Division of the U.S. Department of
Justice. Before his government service, Mr. Masoudi was a trial and
litigation partner with the law firm Kirkland & Ellis. Immediately
following his graduation from law school, he clerked for Judge Frank H.
Easterbrook of the U.S. Court of Appeals for the Seventh Circuit.
Mr. Masoudi received his J.D. from The University of Chicago Law School,
graduating with high honors and serving on the editorial board of the
Law Review. He received his B.A. in economics from Amherst College, Phi
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global pharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through gene and
protein regulation. For more information, please visit www.celgene.com.
Follow Celgene on Twitter @Celgene, and on Pinterest and LinkedIn.
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and other reports filed with the Securities and Exchange
Source: Celgene Corporation
News Provided by Acquire Media